About PT-141
A melanocortin receptor agonist studied for sexual function in both men and women, FDA-approved as Vyleesi for hypoactive sexual desire disorder.
Research dose ranges
- Dose: 1000–2000 mcg per administration
- Frequency: 1× per day
- Route: subcutaneous
- Half-life: ~2.7 hours
- Cycle: Continuous
PT-141 is used on an as-needed basis, not daily. The FDA-approved Vyleesi dose is 1.75 mg (1750 mcg) subcutaneously 45 minutes before anticipated sexual activity, no more than once per 24 hours and no more than once per 8 days. Research protocols have studied 1–2 mg.
Storage
Lyophilized vials stable at 2–8°C. Reconstituted solution should be refrigerated and used within 30 days.